



## Zynerba Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference

November 19, 2014

RADNOR, PA – (PR Newswire – November 19, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Oppenheimer 25th Annual Healthcare Conference 2014. The conference will be held December 10 to 11, 2014, at the Crown Plaza Hotel in New York. Chairman and Zynerba CEO Armando Anido will present on Wednesday, December 10, at 8 am ET.

To listen to a webcast of this presentation during the event, please visit the Investor Relations page of [www.zynerba.com](http://www.zynerba.com). A replay of this webcast will be available for 90 days following the conference.

### **About Zynerba Pharmaceuticals**

Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of cannabinoids. Transdermal delivery reduces adverse effects associated with oral dosing. ZYN001 will be studied in chronic cancer pain, fibromyalgia, and peripheral neuropathic pain utilizing a synthetically manufactured prodrug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. Zynerba expects to initiate ZYN001 Phase 1 clinical studies in 3Q 2015. ZYN002 will be studied in refractory epilepsy and osteoarthritis utilizing a proprietary gel formulated to deliver synthetically manufactured cannabidiol (CBD), a non-psychoactive cannabinoid, through the skin and into the bloodstream. Zynerba expects to initiate ZYN002 Phase 1 clinical studies in 3Q 2015. Learn more at [www.zynerba.com](http://www.zynerba.com) and follow the company on Twitter at @ZynerbaPharma.

### **Investor Contact**

Armando Anido  
Chairman and CEO  
Zynerba Pharmaceuticals  
610.263.0163

### **Media Contact**

Jennifer Guinan  
Sage Strategic Marketing  
610.410.8111  
[Jennifer@sagestrat.com](mailto:Jennifer@sagestrat.com)